Table 1.

Baseline characteristics of patients with idiopathic membranous nephropathy

Number of subjects (% male)129 (68%)
Age at time of biopsy (years)a51 (43 to 61)
Time between biopsy and urine analysis (months)a2 (1 to 4)
Survival time (months)a25 (13 to 51)
MAP (mmHg)a97 (86 to 106)
Laboratorya
    serum creatinine (μmol/L)88 (76 to 103)
    serum albumin (g/L)23 (19 to 28)
    serum cholesterol (mmol/L)7.3 (5.7 to 9.2)
    eGFRMDRD4 (ml/min per 1.73 m2)75 (60 to 87)
Urine samples
    proteinuria (g/10 mmol creatinine)a8.0 (5.6 to 10.7)
        proteinuria <4.0 g/10 mmol (%)9
        proteinuria ≥4.0 and <8.0 g/10 mmol (%)41
        proteinuria ≥8.0 and <12 g/10 mmol (%)35
        proteinuria ≥12 g/10 mmol (%)15
    β2-microglobulin (μg/min)a0.6 (0.2 to 4.8)
    α1-microglobulin (μg/min)a41 (23 to 72)
    IgG (mg/24 h)a257 (116 to 490)
    β2-microglobulin (mg/10 mmol creatinine)a0.9 (0.3 to 7.0)
    α1-microglobulin (mg/10 mmol creatinine)a36 (57 to 113)
    IgG (mg/10 mmol creatinine)a262 (110 to 485)
    Selectivity indexb0.19 ± 0.09
Medication (%)
    ACEi/ARB use at time of biopsy22
    ACEi/ARB use during follow-up99
    statin use at time of biopsy13
    statin use during follow-up90
Outcomes
    progression (%)47
        50% rise in serum creatinine (n)30
        25% rise and serum creatinine ≥135 μmol/L (n)24
        clinical progression (n)6
    spontaneous remission (%)47
        partial remission [<2 g/10 mmol] (n)61
        partial remission [<3.5 g/10 mmol and 50% reduction] (n)63
        complete remission (%) (n)26
  • MAP, mean arterial pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFRMDRD4, estimated GFR calculated with the Modification of Diet in Renal Disease formula.

  • a Values are median with interquartile range in parentheses.

  • b Values are means ± SD.